# US 2026/0306761 A1 · Inhalation therapy device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0306761 A1
- Document ID: US20260306761A1
- Status: Published application
- Kind: A1
- Application number: 19/481,976
- Filed: 2024-05-15
- Published: 2026-10-08
- Earliest claimed: 2023-05-15
- Assignees: PARI Pharma GmbH
- Applicants: PARI Pharma GmbH
- Inventors: Carolin Stoeckl; Tobias Hoffmann; Benjamin Heine; Markus Reinhart; Thomas Denis
- Web page: https://patentgrep.com/patent/US20260306761A1

## CPC

- A61M 15/0085: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- A61M 11/001: {Particle size control}
- A61M 11/005: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- A61M 16/022: {Control means therefor}
- A61M 16/142: {with semi-permeable walls separating the liquid from the respiratory gas}
- A61M 2016/0018: {electrical}
- A61M 2016/0027: {pressure meter}
- A61M 2016/0033: {electrical}
- A61M 2207/00: Methods of manufacture, assembly or production
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}

## Abstract

The disclosure concerns an inhalation therapy device inter alia comprising: a sensor (47) configured to detect a flow parameter of the flow in a flow path (7), a controller (18) configured to conclude based on the output of the sensor (47) at least on an inhalation phase and/or an exhalation phase of a user and to, during a single treatment time, repeatedly operate an actuator (6) during a period of the inhalation phase and not operate the actuator (6) during a period of the exhalation phase, wherein an aerosol output rate of the inhalation therapy device at the first opening (8) during the single treatment time is, when using a test solution of albuterol 0.1% (M/V) concentration in 0.9% sodium chloride as the liquid, at least 0.48 g/min at a Median Mass Diameter of aerosol droplets between 4.5 μm and 5.0 μm, or at least 0.42 g/min at a Median Mass Diameter of aerosol droplets between 4.0 μm and 4.5 μm, or at least 0.29 g/min at a Median Mass Diameter of aerosol droplets between 3.5 μm and 4.0 μm, or at least 0.20 g/min at a Median Mass Diameter of aerosol droplets between 3.0 μm and 3.5 pμm, or at least 0.13 g/min at a Median Mass Diameter of aerosol droplets between 2.5 μm and 3.0 μm.

## Claims

### Claim 1

Inhalation therapy device comprising:
a housing body,
a reservoir for holding a liquid in the housing body,
a membrane disposed in the housing body and having a plurality of apertures, wherein the liquid is suppliable to a first side of the membrane by gravitational force;
an actuator coupled to the membrane for vibrating the membrane, whereby the liquid passes through the apertures and an aerosol is generated at a second side of the membrane opposite to the first side;
a flow path being defined in the housing body and having a first opening to the outside of the housing body at one end and at least one second opening to the outside of the housing body at another end, so that a flow is generatable in a first flow direction from the second opening to the first opening in the flow path upon inhalation of a user at the first opening for entraining and delivering the generated aerosol, and/or in a second flow direction from the first opening to the second opening in the flow path upon exhalation of a user at the first opening;
a sensor configured to detect a flow parameter of the flow in the flow path,
a controller configured to conclude based on the output of the sensor at least on an inhalation phase and/or an exhalation phase of a user and to, during a single treatment time, repeatedly operate the actuator during a period of the inhalation phase and not operate the actuator during a period of the exhalation phase,
wherein an aerosol output rate of the inhalation therapy device at the first opening during the single treatment time is, when using a test solution of albuterol 0.1% (M/V) concentration in 0.9% sodium chloride as the liquid,
a) at least 0.48 g/min, optionally at least 0.64 g/min and more optionally at least 0.8 g/min at a Median Mass Diameter of aerosol droplets between 4.5 μm and 5.0 μm, or
b) at least 0.42 g/min, optionally at least 0.54 g/min and more optionally at least 0.70 g/min at a Median Mass Diameter of aerosol droplets between 4.0 μm and 4.5 μm, or
c) at least 0.29 g/min, optionally at least 0.38 g/min and more optionally at least 0.51 g/min at a Median Mass Diameter of aerosol droplets between 3.5 μm and 4.0 μm, or
d) at least 0.20 g/min, optionally at least 0.29 g/min and more optionally at least 0.38 g/min at a Median Mass Diameter of aerosol droplets between 3.0 μm and 3.5 μm, or
e) at least 0.13 g/min, optionally at least 0.19 g/min and more optionally at least 0.26 g/min at a Median Mass Diameter of aerosol droplets between 2.5 μm and 3.0 μm.

### Claim 2 (depends on 1)

The inhalation therapy device as defined in claim 1, wherein the controller is configured to, within each breathing cycle including one inhalation phase and one exhalation phase, start operating the actuator within the exhalation phase and before the inhalation phase starts.

### Claim 3 (depends on 1)

The inhalation therapy device as defined in claim 1, further comprising a storage chamber formed between the membrane and the second opening.

### Claim 4 (depends on 3)

The inhalation therapy device as defined in claim 3, wherein the volume of the storage chamber is between 10 ml and 100 ml, optionally between 20 ml and 80 ml, more optionally between 25 ml and 75 ml.

### Claim 5 (depends on 1)

The inhalation therapy device as defined in claim 1, wherein the sensor is configured to sense the flow parameter at the membrane or between the membrane and the second opening.

### Claim 6 (depends on 1)

The inhalation therapy device as defined in claim 1, wherein the membrane is disposed in the flow path, whereby an envelope flow about at least part of the circumference of the membrane is formed.

### Claim 7 (depends on 1)

The inhalation therapy device as defined in claim 1, wherein the controller is configured to, within each breathing cycle including one inhalation phase and one exhalation phase stop operating the actuator within the inhalation phase and before the exhalation phase starts.

### Claim 8 (depends on 1)

The inhalation therapy device as defined in claim 1, further comprising a mixing chamber formed between the membrane and the first opening.

### Claim 9 (depends on 7)

The inhalation therapy device as defined in claim 7, wherein the volume of the mixing chamber is between 5 ml and 50 ml.

### Claim 10 (depends on 8)

The inhalation therapy device as defined in claim 8, wherein the mixing chamber tapers towards the first opening.

### Claim 11 (depends on 1)

The inhalation therapy device as defined in claim 1, wherein the flow parameter is a pressure, optionally a differential pressure and more optionally a differential pressure between the pressure in the flow path and ambient pressure.

### Claim 12 (depends on 1)

The inhalation therapy device as defined in claim 1, wherein the flow path is configured to provide a first flow resistance upon inhalation of a user and second flow resistance upon exhalation of the user lower than the first flow resistance upon inhalation and optionally the second flow resistance upon exhalation of the user is at least 25% lower than the first flow resistance upon inhalation.

### Claim 13 (depends on 1)

The inhalation therapy device as defined in claim 1, wherein the first flow resistance is between 1.25 times and 6 times larger than the second flow resistance.

### Claim 14 (depends on 1)

The inhalation therapy device as defined in claim 1, wherein the apertures penetrate the membrane in an extension direction from the first side to the second side, each aperture having along its extension direction at the second side a nozzle portion, wherein the length of the nozzle portion is between 5 μm and 16 μm.

### Claim 15 (depends on 14)

The inhalation therapy device as defined in claim 14, wherein the apertures are laser drilled formed in at least two stages, one stage forming the nozzle portion and the remaining stage forming the remainder of the apertures.
